HALOHalozyme Therapeutics Inc.
HALO
Halozyme Therapeutics Inc.4,930
Mkt Cap
$7.58BVolume
978,028.0052W High
$82.2252W Low
$47.50PE Ratio
25.67HALO Fundamentals
Price
$63.96Prev Close
$63.66Open
$63.4850D MA
$66.14Beta
0.74Avg. Volume
1.39MEPS (Annual)
$2.56P/B
154.33Rev/Employee
$3.3M$10,373.12
Vanguard Group Inc. Sells 62,890 Shares of Halozyme Therapeutics, Inc. $HALO
Vanguard Group Inc. decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,566,896 shares of the biopharmaceutical company's stock after selling 62,89...
MarketBeat·3h ago
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been given a consensus recommendation of "Hold" by the twelve brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and...
MarketBeat·9h ago
Halozyme to Report First Quarter 2026 Financial and Operating Results
Halozyme to Report First Quarter 2026 Financial and Operating Results Halozyme to Report First Quarter 2026 Financial and Operating Results PR Newswire SAN DIEGO, April 30, 2026 SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will...
PR Newswire·3d ago
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3d ago
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
Halozyme Appoints Darren Snellgrove as Chief Financial Officer Halozyme Appoints Darren Snellgrove as Chief Financial Officer PR Newswire SAN DIEGO, April 30, 2026 SAN DIEGO, April 30, 2026...
PR Newswire·3d ago
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
Halozyme Therapeutics (HALO) Expected to Announce Earnings on Tuesday
Halozyme Therapeutics (NASDAQ:HALO) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-halozyme-therapeutics-inc-stock...
MarketBeat·5d ago
Asset Management One Co. Ltd. Increases Stock Position in Halozyme Therapeutics, Inc. $HALO
Asset Management One Co. Ltd. increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 1,358.0% during the fourth quarter, according to its most recent Form 13F...
MarketBeat·9d ago
Boston Trust Walden Corp Sells 52,058 Shares of Halozyme Therapeutics, Inc. $HALO
Boston Trust Walden Corp reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 781,835 shares of the biopharmaceutical company's stock after selling 52,058 s...
MarketBeat·11d ago
Choreo LLC Sells 28,448 Shares of Halozyme Therapeutics, Inc. $HALO
Choreo LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 90.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,075 shares of the biopharmaceutical company's st...
MarketBeat·11d ago
<
1
2
...
>